Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
New information in the 10Q......
Sam Gaer continues to fund TGFN with convertible debt at .01/share. Another $12K on November 13, subsequent to the end of the third quarter.
Also, an interesting bit of information was disclosed in the "results of operations" segment of the quarterly reply......
Operating costs of $15,916 for the three months ended September 30, 2012 increased by $2,119, or 15.4% versus those of the three months ended September 30, 2011, due primarily to additional Selling, General and Administrative costs associated with due diligence of the company’s latest acquisition target company which resulted in an increase of $1,454, or 100% versus those of the three months ended September 30, 2011.
Marshall Butler obituary.....
Marshall Butler passed away last week at the age of 85.
Riverside Memorial obituary.....
BUTLER--Marshall, businessman, philanthropist and supporter of the arts, died at the age of 85 of heart failure at home in New York City where he was surrounded by his loving family. Marshall was respected and admired by associates and friends for the honesty, integrity and generosity that he showed in his business and personal affairs. Mr. Butler co-founded Alloys Unlimited, a sub-components manufacturer for the semi-conductor industry, in 1958. In 1971, the Company merged with Plessy, a manufacturer of telephone equipment and electronic components. That merger was the first between a British company and an American company using ADRs (American Depository Receipts) that allow a stock for stock tax free merger. In 1973, he took over as CEO, and a few years later, as Chairman of AVX Corporation a manufacturer of ceramic capacitors. The company grew to over $500M by 1989 when Mr. Butler facilitated the merger of AVX and Kyocera, the first merger between an American and a Japanese company. He served as a Senior Managing Director of Kyocera until he retired in 1994. At the age of 64, Marshall began a second career as a venture capitalist, where he was a pioneer in attracting foreign venture capital to invest in Israel. His first fund started with $12 million in capital. By the time he retired, Mr. Butler had raised over $600 million and helped fund over 50 Israeli high tech companies. In 1998 he received the Prime Minister's award for his achievements in bringing venture capital to Israel. In addition to his business activities, Marshall was active in many charitable non-profit organizations including The American Technion Society, Israel's most prestigious engineering institution, where he served on the Board of Governors. In 2001, he received an Honorary Doctorate from the Technion. Marshall was a former board member of the Association of Resident Theaters of New York City. He also gave financial support for many years to the United Jewish Appeal and the Anti-Defamation League (ADL). Marshall was born in Manhattan in 1927, and attended the Bronx High School of Science. He served in the U.S. Navy during WWII and attended New York University on the GI Bill. Marshall is survived by his wife of 53 years, Marilyn, and children Hillary, Lawrence, Michael and Eliot and his six grandchildren. He is also survived by his sister, Rhoda and many nieces and nephews. We will all miss his warmth, love and generosity.
BUTLER--Marshall D. We deeply mourn the passing of Marshall D. Butler, an enlightened businessman and a citizen of the world in a true sense of the word. He combined the talent of a financial genius with the humility of one's best friend who cared more about others than himself. He was as much at home in Kyoto or Tokyo as he was in Tel Aviv or Jerusalem, or in uptown Manhattan or Quogue, Long Island. Marshall received his degree in Business Administration from NYU and grew up on West 155th Street in Manhattan. He founded Alloys Unlimited with his friends Hamburg Tang and Greg Coleman, and the company went public and was a very successful semiconductor piece parts manufacturer. Plessey Ltd., a major English electronics corporation, bought Alloys Unlimited some years later. Marshall was asked by investors to join Aerovox Corporation of Myrtle Beach, NC, later called AVX. He quickly became its Chairman and CEO and that company some years later was acquired by Kyocera of Kyoto, Japan in a transaction for shares, never done before by a Japanese company. Kyocera became listed on the NYSE. Marshall remained an important Director of Kyocera. AVX was later partially spun off from Kyocera but Marshall remained close to the founder of Kyocera, Dr. Kazuo Inamori. The Jewish technology businessman and the founder of Kyocera, now KDDI, became immersed in helping others. In Marshall's case, the State of Israel and its great non-profit the Technion Institute. Dr. Inamori founded the Inamori Foundation and created the Kyoto Prize. Marshall served as a Director of Kyocera Venture Capital. Back in America, Marshall also served as a Director of Mass Mutual Corporate Investors and Mass Mutual Participation Investors. As his interest in Israel became more pronounced, Marshall received the Israeli Prime Ministers award for his contribution to Israeli industry and he received an Honoree Doctorate from the Technion Institute. In Israel, Marshall was Chairman of Infinity Private Equity Fund. He was a Director of Tadiran Telecommunications Ltd., Shellcase, Galil Medical Ltd. and in New York he was a member of the NY State Council of Humanities, and A.R.T New York, which manages a host of off Broadway theaters Back in Israel, he became a Director of Syneron Medical Ltd., which later went public in the U.S. One rarely meets a man as devoted to quality in his business activities and generosity, as well, in all he did. He was blessed with a devoted family, his wife Marilyn, his sons, Michael, Elliot, Larry, his daughter, Hillary, and their families, as was well as his friends who will find the future with a little less quality, but also joyously filled with wonderful memories and important examples of how one should live their lives. The Towbin Family
Syneron Medical Announces Death of Longtime Board Member Marshall D. Butler
YOKNEAM, Israel, Nov. 12, 2012 /PRNewswire/ -- Syneron Medical Ltd. (NASDAQ: ELOS), the leading global aesthetic device company, announced the death of Marshall D. Butler, member of the Company's Board of Directors since 2003.
Shimon Eckhouse, Ph.D., Founder and Chairman of the Board of Syneron Medical, said, "Syneron, its Board of Directors, executives and employees are greatly saddened by the passing of a great friend, long-time board member, mentor and supporter. Marshall has been with us from our inception and contributed to the growth and success of Syneron. On behalf of everyone at Syneron, we extend our deep condolences to his family and friends and the many colleagues whose lives he touched."
Marshall Butler joined the Syneron Medical Board of Directors in 2003, helping to guide the Company through a successful initial public offering, secondary offering, business development transactions and periods of rapid revenue growth. In addition to his work with Syneron, Marshall had a long and distinguished business career. He was co- founder and served as a chairman of both First Israel Mezzanine Investors Fund and Israeli Infinity VC Fund. He was a director of Tadiran Telecommunications Ltd., Shellcase, and Galil Medical Ltd. He served as chairman of Nitzanim, AVX-Kyocera VC from 1994 to 2001, CEO and chairman of AVX Corporation from 1974 to 1993 and as director of Kyocera VC from 1990 to 1994. In 1998, Mr. Butler received the Israeli Prime Minister's award for his contribution to Israeli industry.
In addition to his great achievements in the business world, Marshall will be remembered for his work as a philanthropist and supporter of the arts. He was active in many charitable non-profit organizations including The American Technion Society, Israel's most prestigious engineering institution, where he served on the Board of Governors. In 2001, he received an Honorary Doctorate from the Technion. Marshall was a former board member of the Association of Resident Theaters of New York City. He also gave financial support for many years to the United Jewish Appeal and the Anti- Defamation League (ADL).
Marshall was born in Manhattan in 1927, and attended the Bronx High School of Science. He served in the U.S. Navy during Word War II and attended New York University on the GI Bill. Marshall is survived by his wife of 53 years, Marilyn, and children Hillary, Lawrence, Michael and Eliot and his six grandchildren. He is also survived by his sister, Rhoda and many nieces and nephews.
About Syneron Medical Ltd.
Syneron Medical Ltd. (NASDAQ: ELOS) is the leading global aesthetic device company with a comprehensive product portfolio and a global distribution footprint. The Company's technology enables physicians to provide advanced solutions for a broad range of medical-aesthetic applications including body contouring, hair removal, wrinkle reduction, rejuvenation of the skin's appearance through the treatment of superficial benign vascular and pigmented lesions, and the treatment of acne, leg veins and cellulite. The Company sells its products under two distinct brands, Syneron and Candela. Founded in 2000, the corporate, R&D, and manufacturing headquarters for Syneron Medical Ltd. are located in Israel. Syneron also has R&D and manufacturing operations in the US. The Company markets, services and supports its products in 90 countries. It has offices in North America, France, Germany, Italy, Portugal, Spain, UK, Australia, China, Japan, and Hong Kong and distributors worldwide.
Financial numbers...CEO photo.....
Financial numbers for the trailing 12-month period, as of Q3 2012 (September 30).....
YIHG (share price: .10)
13.3M shares outstanding
$1.33M market cap
$24M revenue
$7.4M net income
.55 EPS
.18 PE
$1.48 book value
Yakun Song (YIHG CEO) attended a donation/check presentation ceremony at Hong Kong Baptist University last week, in her role as the Honorary President/Chairman of a foundation/fund that the university has. She has donated money a couple of years ago to set up some scholarship programs. Song is the second from the left.....
http://translate.google.com/translate?hl=en&sl=zh-CN&u=http://cn.hkbu.edu.hk/mainland/index.php%3Faction%3Dview%26id%3D562&prev=/search%3Fq%3D%2522song%2Byakun%2522%26num%3D100%26hl%3Den%26lr%3Dlang_zh-CN%26safe%3Doff%26tbo%3Dd%26biw%3D1008%26bih%3D632%26tbs%3Dlr:lang_1zh-CN,qdr:y&sa=X&ei=E_umUNzjNqOXyAGsh4GIAg&ved=0CD0Q7gEwAA
Newspaper article...Li Xiaoling and Baihuazhou.....
The People's Daily Overseas Edition last week had an article about Li Xiaoling and Baihuazhou. The translation seems to be a bit more difficult than usual to understand, but the article talks about Li Xiaoling's accomplishments, bringing Baihuazhou into the public market, and some of the future development items I mentioned in the previous post.
The article contains a picture with a caption of "Baihuazhou CEO Superficial view". I'm not exactly sure who that individual is. Also contains a current photo of Li Xiaoling.....
http://translate.google.com/translate?hl=en&sl=zh-CN&u=http://news.hexun.com/2012-11-07/147672406.html&prev=/search%3Fq%3D%2522%25E7%2599%25BE%25E8%258A%25B1%25E6%25B4%25B2%25E7%25BB%25BF%25E8%2589%25B2%25E8%25B5%2584%25E6%25BA%2590%25EF%25BC%2588%25E4%25B8%25AD%25E5%259B%25BD%25EF%25BC%2589%25E6%258A%2595%25E8%25B5%2584%25E9%259B%2586%25E5%259B%25A2%25E6%259C%2589%25E9%2599%2590%25E5%2585%25AC%25E5%258F%25B8%2522%26num%3D30%26hl%3Den%26safe%3Doff%26sa%3DX%26tbo%3Dd%26biw%3D1008%26bih%3D632%26tbs%3Dqdr:w&sa=X&ei=h5acUL7QOe3ryAGKkYHgCw&ved=0CEkQ7gEwAg
db7...SN_DN shell......
sn_dn .0024 hopefully has substance and not just a pump
temp luvs amy...reverse merger candidate.....
I don't think they ever actually specified it in the first place, at least not officially. It was more a subliminal message in the company name change. They only stated that they were seeking a candidate. Housefly seemed the logical choice.
Navitas Capital...Southern California office.....
Somewhat interesting to note that Navitas Capital (a cleantech venture capital firm) now has an office at the "Suite 350" address. I think this occurred sometime prior to mid-2012.
http://www.navitascap.com/index.php
http://www.navitascap.com/contact.php
510(k) application(s) expected in early 2013.....
According to the VODG website, the company expects to file a 510(k) application(s) sometime during early 2013. Also, interesting to note that endothelial cells are among the differentiated cells the company expects to include in its product line (see the above post regarding an endothelial differentiation medium the company has in the product development pipeline)........
Our current operational strategy involves expanding market penetration of our MSC research products together with considerable expansion of these products. We sell our products directly and through distributors as well. We are presently expanding our stem cell segment of our product line to include differentiated cells derived from MSCs including chondrocytes, endothelial cells and osteoblasts. These products are ideally suited for high through put screening in drug discovery, development and toxicology. We also are expanding our product line to include stem cell products with clinical applications. An initial target includes our MSC cell culture media for use in clinical studies. This includes serum-free, chemically-defined and animal-free media that allows cellular expansion with reduced concern about potential contamination. We have two products in this class that we plan to submit to FDA for approval in early 2013. We are also developing additional clinical products for use in the in-vivo imaging of stem cells and for treatment of articular, ligament and tendon injury in animals.
db7...CDBH shell status......
Potse, any new material out there? Wondering if we are back to being a shell since Qingyu Meng's departure......
VKIN...reply to PM about previous post.....
Personally, I am getting more than a little annoyed/irritated by the way management of VKIN has chosen to handle a number of things regarding its business operations and disclosures of important information. From a retail investor perspective it is extremely frustrating, and it is extremely puzzling to me why management can't seem to get the message and "get its act together".
Selected Transactions:
•Renhuang Pharmaceuticals, Inc., NASD-OTCBB: RHGP Reverse Merger, listed on September 7, 2006.
•Toll road company operating in China., USD 185 million for a management buyout
•Sterling Biotech Ltd., a public pharmaceutical company based in India – Convertible bonds listed in Luxembourg - $ 70 million in 2004 and $ 20 million in 2005
•Aftek Infosys Ltd., a public software developer based in India and Germany – Convertible bonds listed in Luxembourg - $ 33 million in 2005
•Hotel Leela Ventures Ltd., a public five star hotel chain based in India – Convertible bonds - $ 50 million
•Energy Conversion Devices Inc. – a public alternative energy technology company listed on NASDAQ- $ 28 million PIPE in 2003
•Alok Industries Ltd., a home furnishing textile manufacturer based in India – Convertible bonds listed in Luxembourg - $ 60 million in 2005
•Comanche Clean Energy Corp., a ethanol and bio diesel producer based in Brazil – USD 100 million in equity and convertible bonds
•OPG Energy Ltd., a power producer based in India – USD 60 million in equity
db7...NT Publications profile of VKIN.....
It looks like VKIN has been supplying some information to NT Publications for some type of 30-day, unpaid awareness/promotion campaign starting on October 8.
Personally, I am getting more than a little annoyed/irritated by the way management of VKIN has chosen to handle a number of things regarding its business operations and disclosures of important information. From a retail investor perspective it is extremely frustrating, and it is extremely puzzling to me why management can't seem to get the message and "get its act together".
NT Publications profile.....
The Viking Vision is global! Viking Investments vision includes incubating and operating social gaming and gambling in Asia Europe and South America. Their focus is on financing, identifying talent and leadership, as well as providing professional and CFO services. Viking is utilizing proven and successful technologies in hiring staff and preparing websites, assuring interactive functionality for its future gaming business. While focusing on traditional games such as Craps, Black Jack and Slot Machines, Viking will introduce "Fast Poker"! The software for Fast Poker is designed with the IPad, IPod, Blackberry and Android user in mind. With over 500 million internet users in China, Viking Investments is positioned to capitalize on the fast growing gaming business, and the number in China is expected to grow to over 715 million by the end of 2013. As a result of the internet boom in China, online gaming has been steadily growing and Viking Investments Group has the skilled personnel to lead the market.
Viking Investments Group also diversifies their investments by investing in high tech growth oriented businesses. This diversified approach mitigates risk and helps secure safer investments for the benefit of its shareholders.
The long term vision also includes potentially entering the online music network sector, exchange platform for the Healthcare industry and bringing the United States sucessful matchmaking sector to Asia.
Quincy Tam...Noriyuki Kasahara's research lab......
In the "Customer Data" section of the Neuromics website is an image of VODG's stem cells cultured in MSC-Gro media. The image is provided by Quincy Tam (a Staff Research Associate in Noriyuki Kasahara's research laboratory)......
Quincy Tam
Staff Research Associate
Quincy received her bachelor's degree in Molecular, Cell & Developmental Biology from the University of California, Santa Cruz. She worked in medical diagnostics as she continued to pursue her education and became certified in stem cell technology. Quincy joined the Kasahara lab in 2011, and her study focuses on the delivery of RRV (replication retroviral vector) to glioblastoma using stem cell based carriers.
Noriyuki Kasahara, MD, PhD
Director, JCCC Vector Shared Resource & CURE Vector Core Facility
Professor, Departments of Medicine and Molecular & Medical Pharmacology
David Geffen School of Medicine at UCLA
Dr. Kasahara received his medical degree from Tokyo Medical & Dental University in Japan, and completed clinical training and Board certification in Laboratory Medicine / Clinical Pathology at the University of California, San Francisco (UCSF), where he also received his Ph.D. from the Interdepartmental Program in Endocrinology / Physiology. He was previously on the faculty in the Department of Pathology and Institute for Genetic Medicine at the University of Southern California, before being recruited to the UCLA Division of Digestive Diseases in 2003. In addition to being Professor of Medicine and Molecular & Medical Pharmacology at UCLA, Dr. Kasahara serves as Director of the Vector Core Facility for the CURE Digestive Disease Research Center and the Vector Shared Resource for the UCLA Jonsson Comprehensive Cancer Center, and as Associate Medical Director of the HLA Immunogenetics Lab at the Mendez National Institute of Transplantation in Los Angeles. He has served two terms as a member of the Scientific Committee on Viral Gene Transfer Vectors for the American Society of Gene & Cell Therapy (ASGCT), he is a member of the Board of Councilors for the Japan Society of Gene Therapy (JSGT), and is currently President of the International Society for Cell & Gene Therapy of Cancer (ISGCT).
Dr. Kasahara's research program is primarily focused on gene therapy for cancer, transplantation, and regenerative medicine. His lab is currently working on novel therapeutic applications of conventional retrovirus-, lentivirus-, and adenovirus-based vectors, as well as the development of novel gene delivery vector systems, including hybrid adenovirus-retrovirus vectors and replication-competent viruses targeted to cancer cells. Currently funded projects span three different areas: 1) translational development of tumor-selective replicating retroviral vectors (RRV) for gene therapy of cancer, which has recently started clinical trials; 2) genetic engineering of mesenchymal stem cells and cytotoxic T lymphocytes to serve as tumor-homing vector producer cells, and the development of combined strategies for cancer gene therapy and immunotherapy; and 3) genetic modulation of cellular histocompatibility to improve immunological tolerance, and genetic engineering of drug resistance to enable in vivo chemoselection of transplanted cells, for improvement of allogeneic stem cell transplantation.
Some items from the Q3 filing.....
Neuromics.....
During the current fiscal quarter ending July 31, 2012, the Company announced expanded business opportunities with Neuromics, Inc., a current distributor of the Company’s products. The additional opportunities include expanded sales of Vitro’s stem cell products as well as additional products that are perceived to enhance the competitive advantage of the Company’s existing MSC product line by combination with other third party products providing enhanced opportunities for customers, including clinical development of adult stem cell technology. Through evaluations that are ongoing, additional complementary products are being added to the Neuromics, Inc. product line. We anticipate further additional activities leading to expansion of revenue generation through our distribution agreement with Neuromics, Inc.
We are also attended the International Society for Cellular Therapy during the present fiscal quarter and the business opportunities resulting from this have yielded another, separate agreement for distribution of the Company’s entire product line into certain Chinese provinces through StemGenesis, Inc, a stem cell company located in Qingdao, Shandong Province, China and with operations in the USA as well.
The Company now has out-licensed two of its patents covering technology for the generation and purification of FSH, a hormone used to treat infertility. Management of the Company maintains close association with the licensee and is assisting the licensee to develop this business through establishment of distribution channels and related activities. We received a license fee in 2011 and are entitled to royalty payments from product sales. These activities are being accelerated since there has been substantial progress during the early portion of 2012 in the establishment of global distribution channels. Furthermore, the regulatory process of gaining approval to market these products has been advanced through the location of a manufacturing partner. This activity has led to the drafting of registration filings seeking marketing approval for Vitropin™, the Company’s highly purified urofollitropin product and related products in certain foreign countries by the licensee. Since the market for pharmaceutical treatment of infertility is estimated to be quite substantial, capture of even a small portion of the total market can have a positive impact to the Company’s financial position since royalty income is largely transferred to net income because of minimal associated expenses.
Product improvements during the present quarter have focused on our clinical grade MSC-Gro™ media and the addition of new stem-cell derived products including differentiated cells derived from the Company’s adult MSC cell lines. The latter products may be utilized for high throughput screening applications in new drug discovery & development and represent a consumable product since the differentiated cells are not capable of further proliferation. We have now introduced human MSC-derived chondrocytes and plan related additional line extensions during the fourth fiscal quarter of 2012. These cells are useful in the development of new drugs for the treatment of arthritis and osteo-arthritis.
The Company has defined and prioritized its stem cell product pipeline that is primarily designed to yield products for clinical testing of adult stem cells for various applications in injury/disease treatment and regenerative medicine. The products being developed are primarily medical devices and animal therapeutic products that have shorter and less expensive pathways to regulatory approval than new drugs or biologics. Medical devices receive FDA authorization by filing a request for marketing approval known as a 510K filing. This filing requires laboratory testing comparing the performance a new product with another similar product that has already received US FDA 510K approval without the necessity of clinical trials. The Company is presently focused on the development and 510K-filing of its clinical grade MSC-Gro™ media products. Management believes that there is a substantial market for such products in clinical development programs focused on human MSCs both in the US and abroad, including China where the Company now has an alliance partner, StemGenesis, Inc. The regulatory approval of medical devices in China is accelerated by prior FDA approval of a 510K filing, as the Company is planning.
Additional pipeline products include tools for in-vivo imaging of human MSCs and animal MSCs, including equine MSCs that are now in early stage development by the Company.
The Company also filed a new US patent application covering its intellectual property related to the development of its MSC-based clinical products.
Future development plans.....
Also available on the Chinese version of the website is a list of future development plans. Value-added products/operations, bamboo processing, food production activity, etc........
The Five Mountain House original precious forest known as the world's most perfect plant specimens library, and grafting techniques and tissue culture technology in a leading position in the industry.Based on this, the company's future development plan as follows:
• 3,000 acres of virgin forest base for the extension of the five House Hill, New ancient bonsai tree stump 100,000, unconventional seedlings 500,000, more valuable trees to extend the industrial chain construction.
• Relying on the Five Mountain House base of virgin forest, the formation of Jiangxi, Fujian, Anhui, Zhejiang, Guangdong, the largest ecological agricultural and forestry products market.
• Add 2,000 acres of mountain praecox economic forest, the establishment of the natural bamboo fiber laboratory and the processing plants.
• transformation of existing natural Camellia Forest, take the "company + base + farmers" business model, the new 300 acres of Camellia seedling bases and oil tea factory; refining natural, organic, pure green upscale camellia oil.
• build the largest high-end luxury nursery stock base, sound the extended wood carving, root carving, upscale bonsai whole industry chain.
• Relying on 30,000 acres of provincial food basket demonstration garden, and construction of pollution-free food industry base.
• Joint State Forestry Administration, the Ministry of Science and Technology, China Forestry University and other units to set up a national laboratory of yew cum upscale seedlings; Pueraria praecox, wild camellia oil laboratory; achieve two independent breeding laboratory and supporting three test base .
Strategic agreement with Shangrao City Landscaping Authority.....
Based on a news item that appears on the Chinese version of the website, on September 12 the company entered into a long-term cooperation agreement with the Shangrao City Landscaping Authority......
The company signed a strategic cooperation agreement with Shangrao Bureau of Parks
Green Baihuazhou Resources (China) Investment Group Co., Ltd.
The landscaping Authority Shangrao City
Signed a strategic cooperation agreement to build Shangrao ecological garden city
To further creating an ecological garden city, with the guidelines of the the Shangrao City to "comprehensively improve the urban construction and management level, and continue to improve the urban living environment, enhance the city's image and taste, creating a national ecological garden city", the support of the implementation of the municipal government requirements of listed companies, green Baihuazhou Resources (China) Investment Group Co., Ltd. signed a product supply landscaping strategic cooperation agreement of intent "on September 12, 2012 Shangrao City Landscaping Authority. Agreement to the overall goal to build eco-garden city of Shangrao City, Shangrao City, the scale of the landscape construction cycle, as well as the cooperation of the parties to the agreement, job content, working methods and reached broad consensus.
The bright spot is that the signing of the agreement Shangrao City Landscaping Authority through a to examine Baihuazhou Green Resource Investment Group (China) Co., Ltd. after a few seedlings, flowers, bonsai base within the scope of the area that the company's base in both conventional green seedlings, there are special varieties of garden configuration required, after careful consultation and good faith, mutual benefit, cooperation and win-win principle of complementary advantages, landscaping products supply related matters reached a cooperation agreement.
The signing of the agreement will further promote Baihuazhou Green Resources Group Co., Ltd. (China) Investment landscaping business to the whole industry chain development, enhance the green Baihuazhou resources strategic positioning Investment Group Co., Ltd. (China), in promoting the company's internal and Shangrao City garden industry resource integration has played a positive role. At the same time, also marks the green Baihuazhou Resources (China) Investment Group Co., Ltd. opened an important chapter in the implementation of a new management model.
Since founded soon to determine the long-term development of strategic objectives and accurate market positioning, has a great competitive advantage in the landscaping market enjoys a high reputation and popularity in the industry peers. Over the years, the company has made impressive achievements in the Shangrao City authorities courtyard, tourist attractions, colleges, real estate, factories, municipal roads and other landscaping projects.
By the listing of opportunity in the United States, the company's efforts to build a domestic regularization modern landscape scale leading enterprises. The company signed a long-term strategic cooperation agreement, the Shangrao City landscaping Authority for the future development of the company "bigger, stronger, doing fine" and laid a good foundation.
Company to design a high starting point, high-quality production, the construction of a high standard, high-performance management, in order to create quality tree brand responsibility, striving for outstanding garden enterprises as the target, and make greater contributions to promote the landscaping career development, beautify the social environment .
Sam Gaer...CEO of Liquid Holdings Group.....
Sam Gaer (TGFN's financial backer and largest shareholder) left his position of CIO and executive vice president of FINRA in May 2012 to become the CEO of Liquid Holdings Group (a financial services firm)......
http://www.liquidholdingsgroup.com/leadership
StemGenesis...$50M project scheduled for construction......
StemGenesis (www.stemgenesisinc.com) is an US-registered cell therapy technology company. Based in California, the company's business focuses on the market in great China including mainland China, Taiwan and Hong Kong. StemGenesis is involved in two cell therapy-related businesses: medical devices and cell therapy.
U.S. stem cell project contract settled Qingdao
Limited project signing ceremony was held on October 25 in Qingdao Development Zone Investment Promotion Bureau actively promote investment by American Gan Yuan Biotechnology Co., Ltd. (StemGenesis) Qingdao Bo yuan medical polymer materials. City, China Merchants Development Zone Management Committee leaders attended the signing ceremony.
Investors of the project for the U.S. Gan Yuan Biotechnology Co., Ltd. (StemGenesis), a total investment of $ 50 million. An investment of $ 30 million, $ 10 million of registered capital.
Qingdao Bo yuan medical projects constructed in two phases, one of the main products and the scale of construction is sterile cord blood and umbilical cord collection and processing refrigeration system, including umbilical cord blood collection bag, SCR-1000 stem cells and then integrated tube, CRYOPRO cord blood frozen bags cord blood processing bags AXP special bags, RQ dedicated pipe, stem cells View accessories combination of stem cell products. Two main products and building scale is automatic stem cell separation system and stem cell activating system, including swinging bucket transfected cell separator bag donor cells regulating system, and adipose tissue extraction and processing system, and bone marrow stem cells concentrated system, mononuclear cells regulating device , thrombin concentration system products.
Settled in Qingdao, Qingdao Bo yuan medical material has a very important significance for accelerating the city in the field of stem cell production and R & D to promote the level of health care to improve city life.
Bo yuan of medical materials, Qingdao Development Zone project is progressing well
Changjiang Road neighborhood offices to discuss the introduction of Qingdao Bo Yuan the dry source Biotechnology Co., Ltd. invested and established medical material items, the signing has been settled since October 25, 2011, under the joint efforts of all parties, in January this year, 6 May the successful completion of the procedures for bidding, auction and 31 acres of land use rights, a bio-pharmaceutical projects the international ecological wisdom of the city first settled.
Gan Yuan Biotechnology Co., Ltd., headquartered in California, the company consolidated the Harvard University stem cell research and the world's most advanced stem cell bank built tube experience. Engaged in biological stem cell research, stem cell library construction and management of a new generation of sterile cord blood and cord blood collection system, and automatically stem cell separation system and stem cell activation system, the production of high-tech enterprises.
The project is located in the City of ecological wisdom, planning area of ??31 acres, a total investment of 50 million U.S. dollars, plans constructed in two phases. An investment of $ 20 million, is mainly engaged in the polymer biomedical materials products, including collecting medical equipment, medical collection containers and other products of research and development, marketing and consulting. Qingdao Bo yuan medical materials project, our country involved in the field of high-tech projects, and its successful introduction, the introduction of the corresponding medical high-tech talent to accelerate our region's pace, driven by the rapid development of related industries.
Qingdao Bo Yuan Medical Technology Co., Ltd. (Qingdao) project
Investment in the project is the United States Gan Yuan Biotechnology Co., Ltd., plans a total investment of $ 50 million, a total investment of $ 20 million, the registered capital of $ 10 million, is located in a small west side of Jiangshan Road, Fuchun River Road north, accounting for land 31 acres. The project plans to build a biotechnology industrial park, the main building with an annual output of 90,000 units of cord blood collection bags and 50,005 thousand units of umbilical cord blood processing bag workshop and supporting facilities, the main building consists of the assembly machine shop, mixing tank workshop, sterilization, is a workshop, office buildings, laboratories, warehouses and other.
The project put into production that year, expected operating income of $ 9.932 million (62.57 million yuan), the profit amounted to $ 1,422,500 (8.96 million yuan). The normal average annual operating income (excluding tax) $ 23,249,900, an average annual tax amount of 23.16 million yuan. Total investment rate of return of 17.38%, net profit margin of 13.04% of capital, the project is expected to be 30% annual increments.
Investment in Active-the Gan source biotechnology Co., Ltd. is a high-tech company, registered in the United States has the world's advanced technology and management team, the company combines the experience of Harvard University stem cell research and the world's most advanced stem cell library developed a The new generation of sterile cord blood and umbilical cord collection system, automatic stem cell separation system and stem cell activation system results. The project will work with our university and renowned academician cooperation, the project will generate huge driving effect the introduction of high-tech talent in our region.
Progress: This project is doing the planning and design plans to start the construction of the third quarter of this year.
Celartia bioreactors.....
From the 7/24/2012 VODG press release.....
A strategic goal moving forward, is an additional partner to supply devices needed for FDA-compliant manufacture of clinical materials for use in pre-clinical and clinical studies. These devices are known as bio-reactors that allow for highly controlled and reproducible production of large numbers of stem cells needed to provide therapeutic benefit. Several characteristics of these bioreactors are essential in reaching the demanding goals needed to achieve regulatory compliant manufacturing to support stem cell therapy that maintains rigorous standards of safety and efficacy. We are presently evaluating suitable devices for this application that appear to be well-suited to the required needs, specifications and characteristics.
I have been promoting the capabilities of our new PetakaTM Cell Culturing Systems. My confidence that you will be delighted with these capabilities is based, in part, on the success Dr. Jim Musick, CEO, Vitro Biopharma had culturing our UCB derived Human Mesenchymal Stem Cells.
These cells work "hand in glove" with Petaka. The system enabled Jim to:
•Culture the cells with out the addition of CO2 or humidity (no environmental dehydration)-no incubator required.
•Use less growth media
•Drive the cells into dormancy enabling them to be maintaned, shipped and stored at Room Temperature.
Amir Gal-Or...comments about Marshall Butler.....
Amir Gal-Or's blog on the Infinity Private Equity Fund website included some comments about Marshall Butler. The "Ken Rind" referenced in the blog is "Kenneth W Rind". Rind, a former/(current?) Director of AHAG, is a well-known and extremely successful venture capitalist/investor.
Marshall Butler and Rind have been long-time investment partners and together the two probably have developed as extensive of a network of venture/investment connections as you will find. If AHAG were to ever do a reverse merger in the high technology or biotech/medical industries, Marshall would probably be a key source for that type of RM candidate. Lawrence Butler's primary areas of interest/experience I think focuses around media/consumer types of business.
Excerpt from Amir's blog (March 2012).....
At the risk of dating myself, I’d like to share a story that summarizes how I view the answer to this question. When I took my first steps into the venture industry in the late 1980s, early 1990s, in New York City, l had two mentors. One was Mr. Marshall Butler. He was and continues to be a “people person”. For Mr. Butler, it was mostly about feeling-out the capability of people and estimating personal relationships alongside the facts. My other mentor was Professor Ken Rind. He was all about market research, track records, numbers, forecasts and analysis. I used to say I have the best of both worlds: an art teacher and a science teacher. Who better to learn from? In retrospect and in the overall analysis of which school of thought will more likely lead to success, I would have to say that I believe it’s best to have a little bit of both. Twenty some years of experience later, from my prospective today, I can say having one without the other is like having a half-baked cake. One needs to find a balance between the two, their ying and yang of skill sets and people skills, and exercise both as you approach each turning point and sharp corner.
An example: all three of us, Mr. Butler, Professor Rind and myself, were faced with an Internet deal in the competitive price shopping arena. Professor Rind immediately focused on the technology and numbers related to performance. Mr. Butler immediately focused on the CEO’s background, his team’s motivation and his vision. For me, as an observer, I learned earlier on that the best deals result from when those who exercise these two approaches, though vastly different, manage to somehow arrive at the same conclusion – and thus we have a harmonious marriage of science and art, not to mention a really successful business deal.
Infinity was set up in 1998 by Nitzanim Fund founder Marshall Butler, who also set up the First Israel Mezzanine Fund (FIMI). Butler set up Infinity together with Clal and Ken Rind, and co-opted Amit Frenkel and Yuval Cohen (not to be confused with Yuval Cohen of the JVP fund), and more recently, Galor. Widely connected Butler brought investors such as General Electric Investments and Banque Nationale de Paris to the fund, and his and Rind’s group, which includes Kyocera (a Japanese materials conglomerate) and AVX, a components company sold to Kyocera, where Butler was general manager.
Frenkel, 35, came to Infinity after many years of investment activities in the Clal group: he managed the Clalit fund, after working in Clal Issuances. He holds a BA in accountancy and economics, and an MBA from the University of Michigan. Cohen, 34, with an academic degree in law, and an MBA in financing from the Hebrew University of Jerusalem, was a legal advisor at Clal Issuances, and participated in setting up the group’s venture capital activity.
Frenkel, Cohen and Galor manage the Israeli operation, while Butler and Rind are based in New York, busy with opening doors in the US. “We’re an international fund,” says Cohen, “and that is what makes us special. Many funds, like Vortex, have affiliated offices in the US, but there’s an enormous difference between this and having people who work full-time, as we do.
Rich...International Conference on Emerging Cell Therapies...
Hemogenix CEO Ivan Rich (VODG's strategic partner) will deliver a keynote address/presentation at the 2012 International Conference on Emerging Cell Therapies (October 1, Chicago).
Subject matter of the presentation will be measurement of stem cell potency prior to therapeutic transplantation of the cells.
http://www.omicsonline.org/celltherapy2012/scientific-program.php
Presentation abstract.....
The biology and measurement of stem cell potency and quality for cellular therapeutic transplantation products
Ivan N. Rich
HemoGenix, Inc.,USA
Abstract
Besides ensuring histocompatability between donor and patient, the measurement of cellular potency prior to stem cell
transplantation is probably the most important parameter that will predict whether the stem cell product exhibits engraftment
potential. Stem cell potency is a quantitative measure of biological functionality of the “active ingredients”, without which engraftment will not occur. Since stem cells only proliferate, it is important that the proliferation potential (potency) and ability (quality) are measured, especially for thawed cell products, shortly before transplantation so that the release criteria necessary for use are assessed. Stem cells exist in a continuum of different degrees of primitiveness. Technology is not available to measure different degrees of primitiveness. For hematopoiesis, a minimum of two stem cell types (primitive and
mature) has been found sufficient. The mesenchymal stem cell (MSC) compartment is more difficult to quantify. However,
the same principles apply to both systems. Proliferation is measured for different stem cell populations using a 3-point cell
dose response. The slope or steepness of the response provides a direct measurement of stem cell proliferation potential. The
steeper the slope, the more primitive the cell and the greater the potency. By comparing this to a reference standard of the
same material, the potency ratio is calculated. A single cell dose provides stem cell quality. Release of the product can occur
when both potency and quality are greater than arbitrary limits. These assay principles can comply with regulations and can be
used for virtually any proliferating stem cell product.
Biography
Ivan Rich obtained his Ph.D in 1978 at the University of Ulm, in Germany and performed his postdoctoral studies at the
University of Chicago. Prior to starting HemoGenix, a contract services and assay development company in 2000 where he is
CEO, he was Director of Basic Research in the Division of Bone Marrow Transplantation and Professor at the University of
South Carolina. He has published 50 peer-reviewed articles and edited two books. His primary field of expertise is in
developmental, experimental and applied clinical hematology.
HemoGenix® FDA Master File to Measure Blood Stem Cell Potency for Cellular Therapy Products:
Advanced Tests for Umbilical Cord Blood Stem Cell Transplantation to Help Reduce Engraftment Failure
HemoGenix® announced today that FDA CBER has given HemoGenix®its first Master File Number for an in vitro blood stem cell potency, quality and release assay (HALO®-96 PQR) (1) for cellular therapy products(2) used for stem cell transplantation purposes. HALO®-96 PQR is the first commercially available stem cell potency assay for cellular therapy products. It incorporates the most sensitive readout available to measure changes in the cell’s energy source (ATP) as a function of the potential for stem cells to proliferate. Potency and quality of stem cell therapeutic products are required to be measured prior to use to help predict the engraftment of the cells in the patient. At the present time, tests such as cell number, viability and a stem cell marker called CD34 are routinely used. However, none of these tests specifically measure stem cells and none determine the stem cell biological activity required for a potency assay. The only cell functionality test presently used in this field, especially for umbilical cord blood transplantation, is the colony-forming unit (CFU) assay, which is subjective, non-validated and has been used since the early 1970s. HALO®-96 PQR changes this paradigm. It is particularly needed in the umbilical cord blood stem cell transplantation field by providing an application-specific test incorporating all of the compliance characteristics required not only by regulatory agencies(3) and standards organizations, but also the cord blood community(4).
“Stem cell potency is one of the most important parameters necessary for any therapeutic product, especially stem cells. Without it, the dose cannot be defined and the transplantation physician has no indication as to whether the product will engraft in the patient. The number of cord blood units collected and stored and the number of cord blood stem cell transplantations have increased exponentially over the last 12 years. During this time, significant advancements have been made in pre- and post stem cell transplantation procedures. Yet the tests used during the preparation and processing of the cells have remained unchanged and do not even measure the biological functionality of the stem cells being transplanted. Indeed, the standards organizations responsible for applying regulatory guidance to the community have so far failed to allow any new and alternative assays to be used during cord blood processing. HALO®-96 PQR is the first test that actually quantitatively characterizes and defines the stem cells in cord blood, mobilized peripheral blood or bone marrow as high quality and potent “active ingredients” for release prior to transplantation. Presently, approximately 20% engraftment failure is encountered in cord blood transplantation. HALO®-96 PQR could help reduce the risk of engraftment failure by providing valuable and time-sensitive information on the stem cells prior to use. HALO®-96 PQR complies with the guidelines not only with the cord blood community, but also with regulatory agencies thereby providing a benefit to both the stem cell transplantation center and the patient,” said Ivan Rich, Founder and CEO of HemoGenix® (www.hemogenix.com).
About HemoGenix, Inc.
HemoGenix® is a privately held Contract Research Service and Assay Development Laboratory based in Colorado Springs, Colorado. Specializing in predictive in vitro stem cell toxicity testing, HemoGenix® provides its services to small, medium and many of the largest biopharmaceutical companies. HemoGenix® has developed several assays for stem cell therapy and regenerative medicine applications. These and other patented and proprietary assays are manufactured and produced in Colorado Springs and sold worldwide. HemoGenix® has been responsible for changing the paradigm and bringing in vitro stem cell hemotoxicity testing into the 21st century. With HALO®-96 PQR the company is now also changing the paradigm to become a leader in stem cell therapy assays. To this end, HemoGenix® is a member of the Alliance for Regenerative Medicine and working with other companies to decrease risk and improve safety for the patient.
David Kennan...VKIN's Chief Technology Officer.....
One way to occasionally get an advance look at any significant new developments is to monitor the website for any interesting changes.
In the last week or so, David Kennan's biography has been added to the management section of the VKIN website. Kennan was formerly the CTO of Logical Design Solutions......
Mr. Kennan, an executive, technical architect, and product manager, has been leading Internet technology teams for over 25 years. His management and engineering background ranges from development of complex systems for defense and telecommunications to rapid prototyping and lean development of consumer-facing services and enterprise solutions. Mr. Kennan has been responsible for the technical success of systems serving millions of global users in both regulated and non-regulated industries such as aerospace and pharmaceuticals.
Prior to joining Viking, Mr. Kennan was Chief Technology Officer of Logical Design Solutions, consulting to Fortune 500 enterprises on online strategy. His teams won many awards including a 2006 Web Marketing Association award with Schering Plough, a 2008 IABC Gold Quill award with Caterpillar, and a 2009 Nielsen Norman Group Intranet Design award with McKesson. Mr Kennan’s engineering discipline was honed working in Israel’s high-tech industry from 1989-1996, on projects such as Intel’s Pentium chip design. More recently, Mr. Kennan founded a mobile technology startup.
Mr. Kennan earned academic honors at both Yale University (BA, History) and Bar Ilan University in Ramat Gan, Israel, where he additionally studied Math and Computer Science. Mr Kennan was a founding board member of the award-winning, Philadelphia-based non-profit Moving Traditions
RichieBoy...sub-penny shares, lack of interest, etc.....
Potse what was your all fired rush? You could have quietly accumulated more at a cheaper price.
Nobody watching this summer and all. Is there a reason for your haste? I have been too busy with other plays the market is pretty hot for summer trading been some real movers! So a little hard to understand why you needed those shares all of a sudden. Did you mean to boost the PPS and grab some attention or was it something more complicated...nobody even remotely interested in this right now. Did you pull the trigger thinking a run was coming?
Added to my position...name reservation renewed.....
Picked up 65+K of shares today at one cent.
Shaojun Sun renewed the "Sunrise Mining" name reservation at Nevada on July 16. This followed an almost 5-month period of time in which the name reservation had lapsed......
http://nvsos.gov/sosentitysearch/CorpDetails.aspx?lx8nvq=TOSrX4JOKZmFqzxWZmB9fQ%253d%253d&nt7=0
SUIP/SGBL shell valuations.....
To the person who sent me a private message regarding the post (below) I made on another board in May 2012.......
SU_IP(.002)...shell, 248K block changes hands......
6.9M shares outstanding
5.5M float
14K market cap
More than 3.5% of the SU_IP shell changed hands in an unusually large block of shares at .002 yesterday.
One of the brothers who owns/controls the SU_IP shell also owns/controls the SG_BL shell ($1.25 x $2, bid/ask). There is currently a huge disparity in valuations between these two shells.
There are differences in insider ownership between the shells, so to accurately compare the valuations of these shells you need to adjust the SU_IP share count up to 28.1M shares. A similiar valuation to SG_BL would place SU_IP's share price at around 15 cents.
investorshub.advfn.com/boards/read_msg.aspx?message_id=74163113
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=69177949
VH1 July 30 press release....
The July 30 press release issued by VH1 has a pretty interesting mention of Awestruck Marketing.....
VH1's "Pop Up Video" Returns Monday, August 6 at 12pm ET/PT
LOS ANGELES, July 30, 2012 /PRNewswire/ -- VH1's beloved Emmy Award-nominated music video franchise "Pop Up Video" returns this summer with more of the musical wit, insight and snark that has cemented the series' status as a perennial fan favorite. The new season kicks off Monday,August 6 at 12pm ET/PT on VH1 with a freshly "popped" batch of the latest music videos of fans' favorite artists and songs.
For the first time ever, VH1 will bring the fun of Pop Up Video to Lollapalooza 2012 by putting attendees in the spotlight as stars of their own videos. From August 3rd-5th, festival-goers in Chicago's Grant Park will be able to step into the fun and irreverent world of "Pop Up Video" to an unprecedented degree, in real life via "augmented reality" software. Developed specifically for VH1 by third-party experiential agency AWESTRUCK Marketing, the breakthrough technology will allow fans to see themselves live on a jumbo screen, interacting with music videos from Lollapalooza artists including the Red Hot Chili Peppers, The Black Keys, Fun., B.o.B. and Gary Clark, Jr. In addition, participants will get the full "pop up" treatment via custom bubbles of humorous info about the videos and insider Lollapalooza facts, overseen by the series' actual editorial team. They can then post photos from the experience instantly to Facebook and Twitter through a custom application.
Fans can now use VH1's "Pop Up" creator to build the ultimate "Pop Up" experience. Create your own snark-filled masterpiece and share with friends via Facebook and Twitter here: on.vh1.com/makePop. Fans are also encouraged to tweet using the official hashtag #PopUpVideo and to check out Pop Up Video on social media by following @VH1PopUpVideo and liking the official Facebook page: https://www.facebook.com/popupvideo.
"Pop Up Video" was nominated for two 2012 Creative Arts and Entertainment Emmy Awards, for "Outstanding Special Class Series" and "Outstanding Special Class Writing."
Original co-creator Woody Thompson is an executive producer for Eyeboogie. Executive producing for VH1 are Shelly Tatro, Karla Hidalgo and Jeff Olde.
About AWESTRUCK Marketing:
AWESTRUCK is a full service experiential agency that produces marketing solutions and events that drive measurable results for brands seeking true engagement with their target consumers. And because every experience is an opportunity to connect, they amplify their work via integrated social and digital media. Based in New York and Los Angeles, they conduct world class operations there and everywhere in between.
About VH1
VH1 connects viewers to the music, artists and pop culture that matter to them most with TV series, specials, live events, exclusive online content and public affairs initiatives. VH1 is available in 99 million households in the U.S. VH1 also has an array of digital channels and services including VH1Classic, VH1 Soul, VH1 Mobile, and extensive video on VH1.com. VH1 is a unit of Viacom Inc. (NASDAQ: VIA, VIAB), one of the world's leading creators of programming and content across all media platforms. For more information, go to www.vh1press.com or visit VH1.com, the VH1 Facebook page and @VH1 on Twitter.
SOURCE VH1
Awestruck press release...Comic-Con 2012, CEO picture.....
Awestruck Marketing put out its second press release a couple of weeks ago. It lists all of Awestruck's activities at this year's Comic-Con held in San Diego......
AWESTRUCK takes over at Comic-Con 2012, bringing to life 10 brand experiences at this year's event in San Diego
NEW YORK, July 18, 2012 /PRNewswire/ -- AWESTRUCK has been providing highly successful experiential marketing programs to the world's leading brands for over 13 years and this year at Comic-Con they showed off their skills with ten activations ranging from targeted guerrilla-style executions to large-scale high profile branding.
"We were so excited to be at Comic-Con this year to see so many of our creative ideas come to life at this event and knowing that we helped our clients to successfully engage with consumers. We were proud to showcase how we at AWESTRUCK can create, design, produce and execute multiple experiences through different mediums that really show off our talents," said Robin Potash, President at AWESTRUCK Marketing.
AWESTRUCK this year brought together a collection of experiential activities to Comic-Con for their clients at ABC, FOX Broadcasting, Entertainment One Films, SYFY, Square Enix, Golin Harris, FX Networks, Lionsgate and Iron Sky that ranged from large scale negotiated billboard spaces to guerilla style teams of brand ambassadors.
We secured and designed fleets of Pedi-cabs to transport attendees, VIPs and talent as well as to create branded environments for press and photo opportunities at Comic-Con. The Pedi-cabs were specially built and designed for Fox Animation Domination, ABC's Once Upon a Time and for Square Enix's Sleeping Dogs.
For Fox Broadcasting, each Pedi-cab was specially designed with custom character props to promote their Animation Domination line-up which includes: The Simpsons, The Cleveland Show, Family Guy, American Dad and Bob's Burgers.
An additional fleet of Pedi-cabs was also created for Square Enix's Sleeping Dogs – a video game set in Hong Kong. This program also included free, sponsored rides with custom-outfitted drivers. It also integrated social media, consumers were asked to "Like" Sleeping Dogs on Facebook or follow Sleeping Dogs on Twitter in order to enjoy their free ride.
AWESTRUCK also custom built Pedi-cabs to replicate the Queen's ornate magical carriage from ABC's "Once Upon a Time" to give riders a free ride and a fairy tale like experience at Comic-Con
For Entertainment One, AWESTRUCK created stunt using a cadre of street teams to publicize their film Iron Sky. "AWESTRUCKS's proactive creativity, high energy and on-point execution of our IRON SKY Babe Army stunt at San Diego's Comic-Con International 2012 created a strong and successful presence for our film! We garnered multiple publicity hits and heavy social media traffic thanks to the help of the AWESTRUCK Team!" said Natasha Pietruschka, Manager, Field Publicity & Promotions Entertainment One Films US.
For the Syfy channel, AWESTRUCK helped establish "Defiance" as the biggest entertainment event of the year with a giant 327' x 100' wallscape taking over the south wall of the Marriott Marquis in downtown San Diego. AWESTRUCK sourced and secured this space that went live on July 3rd and ran through Comic-Con.
Fox Home Entertainment was looking to build buzz for the release of "Get the Gringo" on Blu-Ray and DVD. AWESTRUCK created a "Spot the Lucha Wrestler" campaign where a team of professional Lucha wrestlers and ring girls roamed Comic-Con, posing for photos and carry a "ring girl" style score code which featured a "Get The Gringo" QR Code on it. Attendees who took part in the social media experience with the Lucha team received vouchers for a free taco at Lucha Libra Tacos in San Diego. Not only did AWESTRUCK create and execute this experience but they also negotiated the partnership with Lucha Libra Tacos and a special "Get the Gringo" taco that was added to their menu during the promotion.
For FX Networks, AWESTRUCK came up with a simple yet effective solution to make sure their branding became highly visible throughout the event by creating oversized "FX Bags" for all Comic-Con attendees to place all their collected collateral and gifts in one bag. The FX branded bags promoted their shows "Archer" and "Wilfred".
AWESTRUCK was also commissioned by Golin Harris to create a mobile marketing vehicle to travel the country promoting a new confectionery product launch. AWESTRUCK not only created but integrated the tour to coincide with Comic-Con and brought the highly successful mobile tour to this year's event in San Diego. The mobile vehicle is designed to also support an online campaign by providing the confectionery client with staging and branding opportunities as well as branded content through funny and creative video for the campaign website.
For more information and images of the events at Comic-Con please contact us at the addresses below.
AWESTRUCK is a full service experiential agency that produces marketing solutions and events that drive measurable results for brands seeking true engagement with their target consumers. And because every experience is an opportunity to connect, they amplify their work via integrated social and digital media. Based in New York and Los Angeles, they conduct world class operations there and everywhere in between.
For more information about AWESTRUCK Marketing Group
Contact:
Christian Hodgkinson
AWESTRUCK Marketing Group
(917) 497-5714
christian@getawestruck.com
www.getawestruck.com
Jiao Xuding...June 2012 interview......
Jiao Xuding is mentioned in the first paragraph of this July 2012 Oil and Gas Financial Journal (Focus Reports) article.....
In March of this year, China's Ministry of Land and Resources announced that China likely has the largest reserves of shale gas in the world, estimated at 886 trillion cubic feet (TCF). The authorities had by then already trumpeted their ambitions of commercializing shale by 2015. Ultimately, says Jiao Xu Ding, founder of the landmark Chinese oilfield service company Copower, these vast resources may be able to support China's current population for the next three centuries.
Mr. Jiao, you have samilar background with Mr. Huang from HBP. You worked for state-owned oil companies before deciding to do your own business as well as Mr. Huang. He said he felt limited when working in the state-owned system so he established a private company and enjoyed the freedom of innovation. So what was your motivation when leaving the state-owned enterprise and establishing Copower?
I decided to found Copower in light of the market demand. In 1996, there was no private oil and gas service provider. I saw the potencial opportunity and was ready to face the challenges.
At first, we met a lot of barriers and failures, from the respects of talents, technologies, marketing and cash flow, etc. most of them arise from the system of this industry. Copower has spent 16 years dealing with those challenges, and today, we can say proudly: “we are strong now and we will have a bright future!”
How the operative environment for the private companies in oil and gas industry has changed since you established Copower? You told us that there was barely private oil and gas companies in 1990s, wile now we have many of them. What is their function compared with state-owned oil companies?
Every company in oil and gas industry around the world, no matter operating in exploration and production or engineering service, no matter working inside or outside, has to experience the process “something from nothing”, even if it is one of the top 500 companies. It is closely related to the social system, government policies and talent quality, so do private companies operating in our industry.
Since the opening and reform policy was published, Chinese economy has developed at a high and sustainable rate. So does the oil and gas industry.during this period of time, private companies have contributed a lot to this industry, especially the E&P in Changqing oilfield of PetroChina, Shaanxi Yanchang oilfield, and played an indispensible role in Ordos basin.
Now, Daqing oilfield is the largest one Within China. However, the productivity of Changqing oilfield of PetroChina has increased by 5 million tons per year for 5 years. It is going to be more productive than Daqing in 2 years. It would not happen if there were only state-owned enterprises. So private companies are really important.
Both state-owned and private companies operate in the market, and the capital cost declined thanks to the competition. I believe the development of world-class low permeability oilfield will present in front of our eyes in an amazing short time. Today, there are 10, 000 oil wells and more than 3,000 well equipments owned by private copanies in Ordos.
China is a big market for oil and gas. There are internal companies, including three state-owned and many private companies, besides, there are Shell, Total, Widford Oil and Schlumberger eastablishing bases in China. Every company will find its own position here and act as one of the players in Chinese resources E&P.
In 2010, Copower consolidated with Shlumberger and established Schlumberger-Copower limited company. Schlumberger presented its respect for Copower. Why do you believe it will choose Copower as its partner?
As I mentioned before, I established Copower 16 years ago, which was one of the private companies which were established earliest in China. We have recruited many talents and accumulated abundant experience in oilfield exploration and engineering technology service in 16 years, which made us one of the best players here. Schlumberger came here 30 years ago. It has witnessed the influence of private companies on Chinese companies and oil and gas area. At the same time, we have similar industry chain with Schlumberger in oil and gas exploration and production. What’s more important is that we have same goal. I believe we can promote each other and achieve win-win through cooperation.
The five year plan of Copower is two billion RMB annual revenue and going public overseas within 3 years. So what is your strategy to do this?
Copower is a comprehensive company and majoring in oil and gas field exploration and production and engineering technology service. Both of the two businesses will go public in future.
Now we have cooperated with Sinopec, CNPC and Shaanxi Yanchang Petroleum group on exploration and production. Copower started merger and acquisition in the USA and Angola. Our goal is to be international.
In past 4 years, Copower has established the strategic partnership with companies from a lot of countries, including some from Malaysia, South Korea and Swiss. We are enlarging our international business. Besides cooperating with Schlumberger, we have other area we want to dabble in. you may have heard, the shale gas reserve in China rank No.1 in the world. Some experts said it may support all chinese people for 300 years. I think service providers will be needed in such a big market.
Because of the increasing number of exploration and production overseas of Chinese companies, they need Chinese service companies to go outside. We are working on this and focused on how to maximize the value of these markets.
Now there is no large-sized private companies in oil and gas field exploration, production and service providing. In the long run, it matches national policies and market requirement for Copower to be a large-sized company. Today, we have overcome some technology limites and have a team of talents from BP, Schlumberger or ConocoPhillips.
You have improved your management ability through accumulating working experience and studied in Xi’an Jiaotong university on the MBA doctorate degree last year. What do you think is the key ability Chinese managers need to internationalize their companies?
First, we should understand our strategic goal of our company. Second, we should develop the company culture. Third, we should know how to learn, innovate and integrate. I think it is one important reason for Schlumberger to choose us as its partner that we have same goal and we pay attention to company culture. “Abiding by law, paying tax, fairness and social responsibility” is our objective. Shlumberger has more than 110 thousand employees from 85 countries with different nationalities and ethnic groups. I always put Company culture in the first position in managing Copower and work for it, to make sure that our employees understand our culture.
Sir, what is your final message to the readers of Oil anf Gas Financial Journal?
It is consistant with the current policies in China what you have interviewed and reported in oil and gas industry. Now it is time for us to be intenational!
Copower has a lot of experience of international cooperation. I am so sure that it will strengthen the relationship between those who want to be partner with us and Copower through participating this special report.
Nice Q1 2012 numbers......
Trailing 12-month numbers as of 3/31/2012.....
$25M revenue
$17M net income
.03 EPS
The China RM company has a tax exemption, so it is able to drop more money down to the bottom line. The very nature of the business will probably produce "lumpy/bumpy" results over shorter periods of comparisons, but it appears that some of the China/local government greening policies that were put in place during 2011 should produce some potentially nice growth for DION in the coming years. It also looks like they may be increasing efforts at some point to produce more "value-added" types of products (for example, edible oils, herbal products, etc) using their natural resource items.
It appears that the company's licenses and access to resources has become quite valuable due to market demand and significantly increasing prices on many of the plants/products the company is involved with.
Q1 2012 revenue.....
For the three months ended March 31, 2012, we reported revenue of $7,213,929, an increase of $6,428,000 or 818%, from revenue of $785,929 for the three months ended March 31, 2011. The significant revenue increase was driven by three sales contracts we entered into with Guanrui Real Estates, Jiyang Real Estates, and Jiangxi Phoenix Gardening Greening Service Co., Ltd., which in total represented 57% of revenue for the reporting period. Most of our customers are contractors of the Key Greening Projects approved by the local government of Shangrao. The Key Greening Projects, planned and announced in 2011, comprise the development and construction with governmental funding of certain public parks, landscape zones, infrastructures, and tourism, sightseeing and hospitality projects in the municipality of Shangrao and surrounding counties. To guaranty a stable supply of nursery plants, contractors of the Key Greening Projects generally enter into large-volume contracts with major suppliers like us. Therefore, our revenue during the first quarter 2012 has gone up significantly compared with same period last year. In addition, the contractors with public funds granted by the governments tend to pay a higher price for in-time delivery, which further enhanced our revenue.
Net income for the three months ended March 31, 2012 increased by $5,131,799, or 1212%, to $5,555,294, as compared to $423,495 for the three months ended March 31, 2011. The movement is primarily driven by the increase in sales in terms of volume and price.
The rise in price was mainly due to market demand, which relates to the government supporting policy for urban greening work and city greening coverage. Both Jiangxi and Fujian (one of our major sales provinces for stump and bonsai products) provincial government have announced a “Four Trees” policy in 2011 which means, all the cities in Jiangxi and Fujian should improve the urban greening coverage by four times. The favorable policy opened vast market capacity to us. Moreover, we hold an exclusive thirty year plants harvesting license over Mount Wufu, which contains vast and rich plant specimens, for this reason, we are competitive in plants supplying of different species.
BaiHuaZhou website.....
The website for the RM company started coming online this past Saturday.
China version.....
http://www.baihuazhouchina.com/
English version.....
http://www.baihuazhouchina.com/e_index.asp#
tomsimeo...encouraging activity/developments.....
Based on the changes in content and language on SBAT's website and other related social media sites in the last 1-2 weeks, it appears to me that what is basically a full reverse merger of Viking Investments Group into Sinocubate (SBAT) has now been completed. Have all assets/liabilities and all global operational activities of Viking Investments Group now been transferred to SBAT?
I am hoping that is indeed the case, because in my opinion the "bits and pieces" kind of approach that has been taken up to this point has been needlessly confusing and frustrating from a retail investor standpoint. I realize that changing market conditions and other factors may have played a role in all of this, but it would have been nice to just see a relatively simple straight-forward reverse merger between SBAT and Viking right from the start.
I am assuming that you are waiting for the stock symbol change to take place before there is an increased amount of news flow, but hopefully in any upcoming press releases and the next 1-2 quarterly reports you can provide a very clear and detailed status of SBAT.
Some items I would like to see addressed relatively soon include.....
1) Updated, fully-diluted share structure following any transactions related to the transfer of these additional Viking assets/operations to SBAT. Also, any anticipated additional dilution or debt that might be associated with this transfer.
2) If there remains any part of Viking Nevis that hasn't been transferred, it needs to be fully disclosed and explained. Any current or anticipated/potential future relationship/agreements between SBAT and Viking Nevis (or parties related to Viking Nevis) need to be fully disclosed and explained.
3) Exact nature of and the reason for the establishment of a Series C preferred shares.
http://nvsos.gov/sosentitysearch/corpActions.aspx?lx8nvq=1PiUL4VzUawEuEobAeh4Rw%253d%253d&CorpName=VIKING+INVESTMENTS+GROUP%2c+INC.
4) Any information related to the private placement you are preparing to do (as per SBAT's Facebook page, April 19).
We are currently preparing a Private Placement Memorandum (PPM), enabling investors to invest directly in our company, to be used for our expansion and increased operation.
bababooyah...CFON distribution.....
CFON - Potse did you receive your CFON cash dividend yet?
CFON...final liquidation distribution.....
That makes Robert Sillerman's acquisition of the GWAY/FNCX shell (4M outstanding, 15-12G filer) somewhat of an eyebrow raiser. It could quite possibly renew interest and speculation in low-share structure pink sheet shells. That is why I plan on maintaining the decent-sized positions I have built in 15-12G filing shells like AHAG and CFON.
Neuromics profile of James Musick......
Last paragraph of the Musick profile on Neuromics CEO Pete Shuster's blog......
In our interview, Jim gave blinding glimpses of the future especially with regard to new products to extend Vitro Biopharma's offering of clinical tools to fully explore the ever-expanding therapeutic applications of MSCs. I am excited about the potential. I will keep you posted as new products are commercialized.
Copower website updated...PDF file......
I think Jiao Xuding is preparing/planning to have his company (Copower Enterprise) listed on one of the Hong Kong exchanges. I recall seeing some Copower job postings in 2011, looking for accounting/governance related people who have experience with Hong Kong listings/IPOs.
Under the guidance of 5-year strategy, Copower Petroleum is
set out to become one of the largest non state-owned upstream
E&P company in China, achieving annual turnover of 2 billion
RMB, net profit 400 million RMB, and offshore listing with
three years.
Ivan Rich...June 15 conference presentation.....
Hemogenix CEO Ivan Rich (VODG's strategic partner) will be the Chairman of the "Stem Cell and Bone Marrow Toxicity" session at the 10th International Conference on Early Toxicity Screening (June 14-15, Seattle).
Rich will also be making a presentation during this session.....
8:30 AM – 9:00 AM
Stem Cell In Vitro Screening Models for Toxicity Testing
(Ivan Rich, Hemogenix; Colorado Springs, CO) Predicting
toxicity is a task stem cells can perform very well. They provide
a wealth of predictive information for the cell system they
supply and maintain. This has been proven many times using
primary stem cells, for example, stem cells of the bloodforming
system. More recently, ES and iPS cells as well as
cells derived from these sources have started to be used to
predict toxicity. This could be an important avenue for many
aspects of drug development and other applications. The
question is whether these new stem cells products exhibit the
same response as their primary stem cell counterparts.
Musick...Twitter account activity begins......
CEO James Musick has had a Twitter account established for awhile now, but up until yesterday the only activity in his account was a single follower. Judging by the increase in activity starting yesterday, he will be making more use of this particular social media avenue in the future......
http://twitter.com/#!/VitroBiopharma
Somewhat interesting to note that Neuromics CEO Pete Shuster (VODG product distributor) and shakerzzz (well-known IHUB momentum player/trader) started following each other's Twitter accounts very recently (perhaps within the last few days).
Pete Shuster's Twitter account.....
http://twitter.com/#!/stratoman1
Neuromics blog...another post about Musick.....
Pete Shuster (CEO of Neuromics, a VODG product distributor) has made two posts about James Musick and Vitro Biopharma on his blog in the last two weeks.......
May 15.....
I will be profiling Dr. Jim Musick of Vitro Biopharma. He manufactures and provides us a wealth of expertise on our Human Mesenchymal Stem Cells (hMSCs) and MSCGroTM Mesenchymal Stem Cell Media. As the demand for these grow, we are receiving a variety of questions on differentiation. Specifically, researchers desire to drive these cells to specific progenitor and cell phenotypes like Osteocytes, Adipocytes and Chondroytes.
Neuromics recently added key products from Dr. Jim Musick and our friends @Vitro Biopharma. These include potent umbilical cord derived human mesenchymal stem cells and MSCGroTM (best of breed growth and differentiation media). These cells are capable of many passages enabling researchers to build large stocks.
We will be posting Jim's profile in several weeks.
SU_IP(.002)...shell, 248K block changes hands......
6.9M shares outstanding
5.5M float
14K market cap
More than 3.5% of the SU_IP shell changed hands in an unusually large block of shares at .002 yesterday.
One of the brothers who owns/controls the SU_IP shell also owns/controls the SG_BL shell ($1.25 x $2, bid/ask). There is currently a huge disparity in valuations between these two shells.
There are differences in insider ownership between the shells, so to accurately compare the valuations of these shells you need to adjust the SU_IP share count up to 28.1M shares. A similiar valuation to SG_BL would place SU_IP's share price at around 15 cents.
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=74163113
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=69177949
Endothelial differentiation medium.....
I am semi-expecting to see VODG at some point during 2012 make a new product announcement --- endothelial differentiation medium. Given the company's apparent increased interest in IR-related activity, I am anticipating VODG will issue a separate press release for this product whenever it is introduced.
The only disclosure that this particular/specific product is working its way through the company's product pipeline was this mention in the 2011 product catalog, which I posted about on another board last year.......
We are currently expanding our menu of MSC differentiation media and plan to announce availability of an endothelial differentiation medium for use in clinical applications of MSCs in treatment of cardiovascular disease in the near future.
VODG(.055)...distributor increases product promotion......
Since about mid-April I have been noticing that CEO Pete Shuster of Neuromics (a VODG product distributor) has been actively promoting Vitro Biopharma's products. I'm not sure to what extent this will contribute to any meaningful/significant improvement in VODG revenue's but Schuster seems to be encouraged by the interest/feedback he has been receiving from customers. This should also gain VODG additional exposure to potential collaborators.
On Saturday morning Pete Shuster posted this on his blog......
Neuromics recently added key products from Dr. Jim Musick and our friends @Vitro Biopharma. These include potent umbilical cord derived human mesenchymal stem cells and MSCGroTM (best of breed growth and differentiation media). These cells are capable of many passages enabling researchers to build large stocks.
We will be posting Jim's profile in several weeks.